Colorectal adenocarcinoma
Not recruitingStudy on Encorafenib, Cetuximab, and FOLFIRI for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer After Progression on Encorafenib and Cetuximab
Study on Encorafenib, Cetuximab, and FOLFIRI for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer After Progression on Encorafenib and Cetuximab
- Disease:Colorectal adenocarcinoma
- Substances:CetuximabEncorafenib+3
Italy- Participants:18–64 years · 65+ years
- Substances:Cetuximab
- Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS










